Amlitelimab is a Monoclonal Antibody owned by Kymab, and is involved in 7 clinical trials, of which 3 were completed, and 4 are ongoing.
Amlitelimab (KY-1005) acts by inhibiting OX40L. OX40 (CD134) is expressed on activated T cells; its ligand, OX40 ligand (OX40L) is expressed on dendritic cells, B cells, and activated endothelial cells. OX40 is up-regulated on both CD4 and CD8 T-cells isolated during GVHD. OX40/OX40L blockade can reduce acute GVHD responses.
The revenue for Amlitelimab is expected to reach a total of $7.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Amlitelimab NPV Report.
Amlitelimab (KY-1005) is under development for the treatment of graft-versus-host disease, mild-to-moderate psoriasis, atopic dermatitis, asthma and other immune mediated disease. It is administered through intravenous and subcutaneous routes as an infusion. The drug candidate is a humanized monoclonal antibody which acts by targeting OX40L. It is developed based on Kymouse technology.
Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals and supplements. Sanofi‘s R&D efforts focus on advancing a combination drugs to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.
The company reported revenues of (Euro) EUR39,175 million for the fiscal year ended December 2021 (FY2021), an increase of 4.8% over FY2020. In FY2021, the company’s operating margin was 20.7%, compared to an operating margin of 37.8% in FY2020. In FY2021, the company recorded a net margin of 15.9%, compared to a net margin of 32.9% in FY2020. The company reported revenues of EUR13,138 million for the third quarter ended September 2022, a decrease of 36.8% over the previous quarter.
Quick View – Amlitelimab
|Highest Development Stage|